Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

APPROVED FOR ALL STAGES OF APC1,2

Michael - a patient with intermediate-risk advanced prostate cancer

MICHAEL, 61

INTERMEDIATE-RISK APC*

MICHAEL, 61

INTERMEDIATE-RISK APC*

PATIENT HISTORY AND DIAGNOSIS

  • Diagnosed with PCa 2 years ago
  • PSA was 6 ng/mL
  • Status post: Ventral hernia repair/mesh; Crohn’s disease
  • DRE: Left side slightly firmer
  • Prostate weight: 80 grams
  • Biopsy: 2 of 12 positive cores; 2 cores chronic prostatitis
  • Gleason score: 6 (3+3)
  • Refused treatment

PERSONAL AND FAMILY HISTORY

  • Divorced chef
  • Father, 81 years of age, has a history of PCa, Gleason score 8 (4+4); successful curative attempt (radical prostatectomy and radiation therapy)
  • Older brother has a history of PCa, Gleason score 7 (3+4), treated with radical prostatectomy at 58 years; recurrence 3 years later and currently on long-term ADT

1 YEAR LATER

  • PSA was 8 ng/mL
  • Recommended repeat biopsy; patient refused

PRESENT VISIT (2 YEARS AFTER DIAGNOSIS)

  • PSA is 16 ng/mL
  • Testosterone level: 435 ng/dL
  • Stage T3a, N0, M0; fixed on left
  • Biopsy: Entire left side positive; 3 of 6 positive cores on right
  • Gleason score: 7 (3+4)

Hypothetical patient based on patient types studied in clinical trials. The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).1

Michael - a patient with intermediate-risk advanced prostate cancer

Abbreviations: ADT = androgen deprivation therapy; APC = advanced prostate cancer; DRE = digital rectal exam; PCa = prostate cancer; PSA = prostate-specific antigen.

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.
Actual physician quote

REFERENCE: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.